FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Symons Julian A.					2. Issuer Name and Ticker or Trading Symbol Aligos Therapeutics, Inc. [ALGS]								eck all applic Directo	able)	ting Person(s) to Iss 10% O		
(Last) (First) (Middle) C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR						3. Date of Earliest Transaction (Month/Day/Year) 02/08/2022							below) See Remarks			below)	,
(Street) SOUTH FRANCI	SCO C	A tate)	94080 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	ndividual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Ta	ble I - Non-D	erivati	ve Se	ecurities	s Ac	auired. D	ispo	sed o	f. or Be	neficially	v Owned				
1. Title of Security (Instr. 3) 2. Tra			Transactio	on	2A. Deem Execution if any	A. Deemed Execution Date,		3. 4. Securiti Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		5. Amour Securitie Beneficia Owned F	s Formally (D) (ollowing (I) (II)		n: Direct Interpret Interpret Indirect Interpret Interpr	7. Nature of Indirect Beneficial Ownership	
								Code V	-	Amount		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
			Table II - Dei (e.ç					uired, Dis , options					Owned			·	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, Transaction Derivative Expiration Date Order		7. Title and of Securiti Underlying Derivative (Instr. 3 and	es g Security	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e s ully	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
				Code	v	(A)	(D)	Date Exercisable	Exp Date	iration e	Title	Amount or Number of Shares		Transacti (Instr. 4)	on(s)		
Stock Option (Right to Buy)	\$3.06	02/04/2022		A		105,000		(1)	02/0	04/2032	Common Stock	105,000	\$0.00	105,00	00	D	
Stock Option (Right to Buy)	\$3.06	02/04/2022		A		26,250		(2)	02/0	04/2032	Common Stock	26,250	\$0.00	26,25	0	D	

1. 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

2. 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date

Remarks:

Executive Vice President, Chief Scientific Officer

/s/ Lucinda Y. Quan, as 02/08/2022 attorney-in fact for Julian A. **Symons**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.